Hemophilia- MCQs

Welcome to your Hemophilia- MCQs

1. Deficiency of which of the following factors is known as parahemoplilia?

A. Factor V

B. Factor VIII

C. Factor VII

D. Factor II

2. Which of the following is a new recombinant humanized IgG4 bispecific antibody used for the treatment of Hemophilia A

A. Eculizumab

B. Emicizumab

C. Abciximab

D. Daratumumumab

3. Which of the following is matched correctly?

A. Adsorbed plasma – lacks factors II and VII

B. Aged plasma -lacks factors II, VII, XI and X

C. Serum – lacks factors I, V and VIII

D. All are correctly matched

4. True regarding FVIII inhibitors is?

A. 90 % of patients with hemophilia A develop persistent inhibitors to FVIII

B. Mixing study with normal plasma when performed results in a delayed correction of APTT, if an inhibitor is present

C. Diagnosis is confirmed by bethesda assay

D. Inhibitor is present when bethesda assay shows levels > 1 BU/ml

5. True regarding hemophilia B leyden?

A. Autosomal recessive disorder

B. It worsens after puberty

C. A steroid receptor is involved in the pathogenesis

D. The frequency is higher than in hemophilia

Your cart (items: 0)

Products in cart
Product	Details	Total
	Available on backorder Previous price: Discounted price:	Save

Your cart (items: 0)